CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 804 enrolled
Drug / intervention
Acetaminophen +1 moredrug
Likely dose
Acetaminophen 2 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04459117
NCT04459117Phase 3Completed

Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen

Institut National de la Santé Et de la Recherche Médicale, France·interventional·Posted Jul 7, 2020·Updated Mar 16, 2026

In Brief

A Phase 3 clinical trial evaluating Acetaminophen and NACL 0.9% for Patency of the Ductus Arteriosus and 2 related conditions. Completed, enrolled 804 participants across 36 sites in 12 countries.

Detailed Summary

TREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth. The Phase II is a dose finding phase in order to assess the minimum effective dose regimen of acetaminophen for the closure of PDA for neonates with a gestational age less than 27 weeks This part of the study will be conducted in 11 NICUs, in 4 countries (France, UK, Finland and Denmark). The Phase III is The phase III is a randomized, multicenter, double-blind, placebo-controlled superiority trial, two arms in a 1:1 ratio, evaluating an increasing of 10% of the percentage of survival without severe morbidity at 36 weeks of post menstrual age. In the intervention arm, 20 mg/kg followed by 7.5 mg/kg quarter in die (QID) will be administered to the 27-28 weeks gestational age group (dosage confirmed through PK/PD data analysis from the previous Finnian study) and the dosage selected after the conclusion of the Phase II will be administered to the 23-26 weeks gestational age group. A group sequential design, with a total of 3 analyses (2 interim analyses and a final) and the O'Brien-Fleming alpha spending function is chosen for the trial. At the same time, a Bayesian sequential analysis is planned for safety endpoints

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Denmark, Estonia, Finland, France, Hungary, Ireland, Italy, Norway, Portugal, Sweden, Switzerland

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJul 7, 2020
Enrollment StartOct 29, 2020
Primary CompletionJun 20, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.0 years ago

Interventions

Acetaminophendrug

In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses). In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.

NACL 0.9%drug

In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses). In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.